Skip to content

Metoclopramide on Gastric Emptying in Mechanically Ventilated Patients

Effects of Metoclopramide Administration on Gastric Emptying in Mechanically Ventilated Critically Ill Patients : A Prospective Randomized Controlled Trial

Status
Completed
Phases
Phase 4
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT05641051
Enrollment
80
Registered
2022-12-07
Start date
2022-12-14
Completion date
2023-06-16
Last updated
2023-06-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Gastric Emptying, Mechanically Ventilation, Metoclopramide, Randomized Controlled Trial

Brief summary

The aim of this study is to evaluate the prokinetic effect of metoclopramide on gastric emptying in critically ill mechanically ventilated patients .

Detailed description

More than 50% of patients in ICU have gastric dysmotility, which leads to slow gastric emptying(GE) and high gastric residual volume (GRV) and is associated with increased mortality in these patients

Interventions

DRUGMetoclopramide

Cases will receive 10 mg intravenous metoclopramide every 6 hours.

DRUGPlacebo

Cases will receive the same volume of IV placebo / 6 hours.

Sponsors

Tanta University
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
DOUBLE (Subject, Investigator)

Masking description

The drugs will be prepared by a dedicated anesthesiologist who is aware of the allocated group and will have no subsequent role in the study.

Eligibility

Sex/Gender
ALL
Age
20 Years to 60 Years
Healthy volunteers
No

Inclusion criteria

1. Patients' age 20 - 60 years. 2. Either gender. 3. Mechanically ventilated head trauma patients. 4. Patients receiving enteral feeding via nasogastric tube.

Exclusion criteria

1. Patients with contraindications to enteral feeding. 2. Patients with extrapyramidal manifestations. 3. Patients with known allergy to metoclopramide. 4. Patients with seizures. 5. Patients with renal or hepatic diseases.

Design outcomes

Primary

MeasureTime frameDescription
Assessment of the risk of aspiration8 hours interval during first 5 days of enteral feedingAspiration risk will be categorized using the system proposed by Ven de Putte and Perlas. As: * patients with empty antrum and gastric residual volume \< 1.5 mL/kg: low risk. * patients with solid contents or gastric residual volume \> 1.5 mL/kg: high risk.

Secondary

MeasureTime frameDescription
Incidence of ventilator associated pneumonia8 hours interval during first 5 days of enteral feedingPneumonia will be defined according to the ATS/IDSA clinical criteria and will be diagnosed if a new or progressive radiographic infiltrate is present and at least two of the three following clinical features are also present: (1) fever higher than 38°C, (2) leukocytosis or leucopenia and (3) purulent secretions. No microbiological confirmation is required for diagnosis of pneumonia. Infectious Diseases. Society of America (IDSA) and the American Thoracic. Society (ATS)
Time of weaning from mechanical ventilationFrom the start of enteral feeding till intensive care discharge through study completion, an average of 6monthsTime of weaning from mechanical ventilation From the start of enteral feeding
Hospital stayFrom the start of enteral feeding till intensive care discharge through study completion, an average of 6monthsHospital stay including intensive care and ward.

Countries

Egypt

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026